In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of ...

With the FDA clearance of an investigational new drug application for SynKIR-310, a phase 1 trial evaluating the agent in ...

During a Case-Based Roundtable® event, Jonathan L. Kaufman, MD, discussed which lines of therapy and at what doses would be ...

Ira Zackon, MD, discusses the results of a real-world study evaluating racial and socioeconomic disparities among patients with chronic lymphocytic leukemia.

Nivolumab with ipilimumab did not lead to progression-free survival benefits in patients with unresectable stage III ...

Currently, carboplatin or cisplatin with etoposide combined with atezolizumab (Tecentriq) or durvalumab (Imfinzi) followed by ...

SNB-101, a nanoparticle drug for small cell lung cancer, received a fast track designation from the FDA for expedited ...

A US health care executive survey found 30% see health equity solely as a social concern. Yet, it's about ensuring everyone has a fair shot at optimal health. Utilizing standardized data can shift ...

The FDA has approved the investigational new drug application of WGc-043, an Epstein-Barr virus-related mRNA cancer vaccine.

IGV-001 is an autologous cell immunotherapy with antisense oligonucleotide targeting IGF-1R. In the phase 1b study, IGV-001 ...

Sima Porten, MD, MPH, discusses the rationale for the phase 3 SunRISe-5 study of TAR-200 in non-muscle invasive bladder ...

MW2821 was granted an orphan drug designation from the FDA and is being evaluated for the potential treatment of esophageal ...